Possible Association Between Vascular Endothelial Growth Factor in Obese and Thin Built Women with PCOS
Keywords:
Vascular Endothelial Growth Factor, Thin, Obese, PCOS.Abstract
Polycystic ovary syndrome is a common infertility disorder affecting a significant proportion of the global population. It is the main cause of anovulatory infertility in women and is the most common endocrinopathy affecting reproductive-aged women, with a prevalence of 8–13% depending on the criteria used and population studied. Vascular endothelial growth factor, which is responsible for promoting the proliferation of vascular endothelial cells and regulating vascular permeability, is of great importance in follicular development. This study aimed to evaluate the role of vascular endothelial growth factor level in obese women and thin built women with Polycystic ovary syndrome. This case control study conducted at the Department of Obstetrics and Gynecology at Babylon Maternity and Pediatric Teaching Hospital, during the period from January 2021 to July 2021. Sixty women were enrolled in the study and divided into three groups: Group A: twenty cases as obese women with Polycystic ovary syndrome, group B: twenty cases as thin women with Polycystic ovary syndrome, group C: twenty healthy women as control group Our findings showed a significant difference found between Polycystic ovarian disease groups (thin and obese) regarding Testosterone, and between the groups. Mean value of Vascular endothelial growth factor was (131.14 ± 106.7) in control group while (281.04 ± 143.1) in thin Polycystic ovary syndrome and in obese Polycystic ovary syndrome was (297.46 ± 159.45). In conclusion, a highly significant increase in Vascular endothelial growth factor level in patients with Polycystic ovary syndrome (thin, and obese) than that in healthy subjects (P<0.001), but with no difference found between Polycystic ovary syndrome group (thin+ obese) regarding Vascular endothelial growth factor level
Downloads
References
Strowitzki T. Advanced diagnosis of polycystic ovary syndrome—new prediction models with standard parameters. Fertility and Sterility. 2021 Jan 1;115(1):92-3.
Kamboj MK, Bonny AE. Polycystic ovary syndrome in adolescence: diagnostic and therapeutic strategies. Translational pediatrics. 2017 Oct;6(4):248.
Goyal A, Ganie MA. Idiopathic Hyperprolactinemia Presenting as Polycystic Ovary Syndrome in Identical Twin Sisters: A Case Report and Literature Review. Cureus. 2018 Jul 19;10(7):e3004.
Albu D, Albu A. The relationship between anti-Müllerian hormone serum level and body mass index in a large cohort of infertile patients. Endocrine. 2019 Jan;63(1):157-163.
Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocrine reviews. 2015 Oct 1;36(5):487-525.
Marciniak A, Lejman-Larysz K, Nawrocka-Rutkowska J, Brodowska A, Songin D. [Polycystic ovary syndrome - current state of knowledge]. Pol Merkur Lekarski. 2018 Jun 27;44(264):296-301.
Sala Elpidio LN, de Alencar JB, Tsuneto PY, Alves HV, Trento Toretta M, It Taura SK, et al. Killer-cell immunoglobulin-like receptors associated with polycystic ovary syndrome. J Reprod Immunol. 2018 Nov;130:1-6.
Shorakae S, Ranasinha S, Abell S, Lambert G, Lambert E, de Courten B, Teede H. Inter-related effects of insulin resistance, hyperandrogenism, sympathetic dysfunction and chronic inflammation in PCOS. Clin Endocrinol (Oxf). 2018 Nov;89(5):628-633.
Leon LI, Mayrin JV. Polycystic Ovarian Disease. StatPearls [Internet]. 2020 Jul 10. Available at: https://www.ncbi.nlm.nih.gov/books/NBK459251/. Accessed on 20/9/2021.
Rosenfield RL. Current concepts of polycystic ovary syndrome pathogenesis. Current opinion in pediatrics. 2020 Oct 1;32(5):698-706.
Ibáñez L, Oberfield SE, Witchel S, Auchus RJ, Chang RJ, Codner E, et al. An international consortium update: pathophysiology, diagnosis, and treatment of polycystic ovarian syndrome in adolescence. Hormone research in paediatrics. 2017; 88:371-95.
Li Y, Lin H, Pan P, Yang D, Zhang Q. Impact of central obesity on women with polycystic ovary syndrome undergoing in vitro fertilization. BioResearch Open Access. 2018 Aug 1;7(1):116-22.
Mani H, Davies MJ, Bodicoat DH, et al. Clinical characteristics of polycystic ovary syndrome: investigating differences in white and South Asian women. Clin Endocrinol (Oxf). 2015;83(4):542–549.
Legro RS, Arslanian SA, Ehrmann DA, et al.; Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. Journal of Clin Endocrinol Metab. 2013;98(12):4565–4592.
Ehrmann DA, Hoeger KM, Murad MH, Pasquali R. Corrigendum to: “Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline”. The Journal of Clinical Endocrinology & Metabolism. 2021;106(6): e2462.
Guzmán A, Hernández‐Coronado CG, Gutiérrez CG, Rosales‐Torres AM. The vascular endothelial growth factor (VEGF) system as a key regulator of ovarian follicle angiogenesis and growth. Mol Reprod Dev. 2023;90(4):201–17.
Peitsidis P, Agrawal R. Role of vascular endothelial growth factor in women with PCO and PCOS: a systematic review. Reprod Biomed Online [Internet]. 2010 Apr 1;20(4):444–52.
Di Pietro M, Pascuali N, Parborell F, Abramovich D. Ovarian angiogenesis in polycystic ovary syndrome. Reproduction. 2018 May 1;155(5):R199-209.
Scotti L, Parborell F, Irusta G, De Zuñiga I, Bisioli C, Pettorossi H, et al. Platelet-derived growth factor BB and DD and angiopoietin1 are altered in follicular fluid from polycystic ovary syndrome patients. Mol Reprod Dev. 2014 Aug;81(8):748-56.
Agrawal R, Sladkevicius P, Engmann L, Conway GS, Payne NN, Bekis J, Tan SL, Campbell S, Jacobs HS: Serum vascular endothelial growth factor concentrations and ovarian stromal blood flow are increased in women with polycystic ovaries. Hum Reprod. 1998, 13: 651-655.
Smet ME, McLennan A. Rotterdam criteria, the end. Australas J Ultrasound Med. 2018 May 17;21(2):59-60.
CDC. Growth Chart Training. Available at: https://www.cdc.gov /nccdphp / dnpao/growthcharts/training/bmiage/page5_1.html.
Lim LY, Seubsman SA, Sleigh A, Bain C. Validity of self-reported abdominal obesity in Thai adults: a comparison of waist circumference, waist-to-hip ratio and waist-to-stature ratio. Nutrition, Metabolism and Cardiovascular Diseases. 2012 Jan 1;22(1):42-9.
Mukaka MM. A guide to appropriate use of correlation coefficient in medical research. Malawi medical journal. 2012;24(3):69-71.
Temur M, Yilmaz O, Aksun S, Ozun Ozbay P, Calan M, Kume T, et al. Increased circulating urocortin-3 levels is associated with polycystic ovary syndrome. Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology. 2016;32(3):218-22.
Temur M, Yilmaz O, Aksun S, Calan M, Ozun Ozbay P, Kumbasar S, et al. The relationship of urocortin-2 with insulin resistance patients having PCOS. Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology. 2017;33(2):124-7.
Ates S, Aydin S, Ozcan P, Soyman Z, Gokmen Karasu AF, Sevket O. Clinical and metabolic characteristics of Turkish adolescents with polycystic ovary syndrome. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology. 2018;38(2):236-40.
Chen X, Ni R, Mo Y, Li L, Yang D. Appropriate BMI levels for PCOS patients in Southern China. Human reproduction (Oxford, England). 2010;25(5):1295-302.
Li L, Zhang F, Cui J, Shi Y, Xiang J, Wang X, et al. Association of betatrophin with metabolic characteristics in overweight/obese and lean women with PCOS. Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology. 2017;33(3):238-43.
Iuhas C-I, Costin N, Niţă C, Mihu D. Body Fat Distribution in Women with Polycystic Ovary Syndrome. 2013;20(2):107.
Mardanian F, Heidari N. Diagnostic value of prostate-specific antigen in women with polycystic ovary syndrome. Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences. 2011;16(8):999-1005.
Behboudi-Gandevani S, Ramezani Tehrani F, Cheraghi L, Azizi F. Could "a body shape index" and "waist to height ratio" predict insulin resistance and metabolic syndrome in polycystic ovary syndrome? Eur. journal of obstetrics, gynecology, and reproductive biology. 2016; 205:110-4.
Haghighatdoost F, Sarrafzadegan N, Mohammadifard N, Asgary S, Boshtam M, Azadbakht L. Assessing body shape index as a risk predictor for cardiovascular diseases and metabolic syndrome among Iranian adults. Nutrition (Burbank, Los Angeles County, Calif). 2014;30(6):636-44.
Mokha JS, Srinivasan SR, Dasmahapatra P, Fernandez C, Chen W, Xu J, et al. Utility of waist-to-height ratio in assessing the status of central obesity and related cardiometabolic risk profile among normal weight and overweight/obese children: the Bogalusa Heart Study. BMC pediatrics. 2010; 10:73.
Saadia Z. Follicle Stimulating Hormone (LH: FSH) Ratio in Polycystic Ovary Syndrome (PCOS)-Obese vs. Non-Obese Women. Medical Archives. 2020 Aug;74(4):289.
Sachdeva G, Gainder S, Suri V, Sachdeva N, Chopra S. Obese and non-obese polycystic ovarian syndrome: Comparison of clinical, metabolic, hormonal parameters, and their differential response to clomiphene. Indian journal of endocrinology and metabolism. 2019 Mar;23(2):257.
Lal L, Bharti A, Perween A. To Study The Status of LH: FSH Ratio in Obese and Non-Obese Patients of Polycystic Ovarian Syndrome. IOSR J Dent Med Sci. 2017; 16(01): 20-23.
Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. Exs (2005) 94):209–31.
Greenaway J, Connor K, Pedersen HG, Coomber BL, LaMarre J, Petrik J. Vascular endothelial growth factor and its receptor, Flk-1/KDR, are cytoprotective in the extravascular compartment of the ovarian follicle. Endocrinology (2004) 145(6):2896–905
Ferrara N, Frantz G, LeCouter J, Dillard-Telm L, Pham T, Draksharapu A, Giordano T, Peale F: Differential expression of the angiogenic factor genes vascular endothelial growth factor (VEGF) and endocrine gland-derived VEGF in normal and polycystic human ovaries. Am J Pathol. 2003, 162: 1881-1893.
Kamat BR, Brown LF, Manseau EJ, Senger DR, Dvorak HF: Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development. Am J Pathol. 1995, 146: 157-165.
Amin AF, Abd el-Aal DE, Darwish AM, Meki AR: Evaluation of the impact of laparoscopic ovarian drilling on Doppler indices of ovarian stromal blood flow, serum vascular endothelial growth factor, and insulin-like growth factor-1 in women with polycystic ovary syndrome. Fertil Steril. 2003, 79: 938-941.
Artini PG, Ruggiero M, Parisen Toldin MR, Monteleone P, Monti M, Cela V, Genazzani AR: Vascular endothelial growth factor and its soluble receptor in patients with polycystic ovary syndrome undergoing IVF. Hum Fertil (Camb). 2009, 12: 40-44.
Harada M, Peegel H, Menon KM. Expression of vascular endothelial growth factor A during ligand-induced down-regulation of luteinizing hormone receptor in the ovary. Mol Cell Endocrinol. 2010; 328:28–33.
Liu MM, Chen XH, Lu XM, Wang FF, Wang C, Liu Y, Li PL, Du BT, Liang S, Gong PD, Wang YX. Variations in the Profiles of Vascular-Related Factors Among Different Sub-Types of Polycystic Ovarian Syndrome in Northern China. Frontiers in Endocrinology. 2021:1078
